Amedeo Smart

Free Medical Literature Service

 

Amedeo

Anemia
  Free Subscription

Articles published in
JAMA
    January 2024
  1. HARRIS E
    Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy.
    JAMA. 2024;331:280.
    >> Share

    October 2023
  2. SIEGAL DM, Belley-Cote EP, Lee SF, Hill S, et al
    Small-Volume Blood Collection Tubes to Reduce Transfusions in Intensive Care: The STRATUS Randomized Clinical Trial.
    JAMA. 2023 Oct 12. doi: 10.1001/jama.2023.20820.
    >> Share

  3. RAASVELD SJ, de Bruin S, Reuland MC, van den Oord C, et al
    Red Blood Cell Transfusion in the Intensive Care Unit.
    JAMA. 2023 Oct 12. doi: 10.1001/jama.2023.20737.
    >> Share

  4. HARRIS E
    Stem Cell Gene Editing Improved Sickle Cell Disease Outcomes.
    JAMA. 2023;330:1218.
    >> Share

    June 2023
  5. HARRIS E
    Daily Dose of Aspirin Linked With Anemia in Older People.
    JAMA. 2023 Jun 28. doi: 10.1001/jama.2023.11954.
    >> Share

  6. WEYAND AC, Chaitoff A, Freed GL, Sholzberg M, et al
    Prevalence of Iron Deficiency and Iron-Deficiency Anemia in US Females Aged 12-21 Years, 2003-2020.
    JAMA. 2023;329:2191-2193.
    >> Share

    February 2023
  7. HARRIS E
    FDA Approves First Oral Treatment for Kidney Disease-Induced Anemia.
    JAMA. 2023 Feb 15. doi: 10.1001/jama.2023.1556.
    >> Share

  8. LARKIN HD
    Sickle Cell Disease Gene Therapy Trial Paused.
    JAMA. 2023;329:364.
    >> Share

    November 2022
  9. VLACHADIS N, Vrachnis N
    A Review of Sickle Cell Disease.
    JAMA. 2022;328:1979.
    >> Share

  10. KAVANAGH PL, Fasipe T, Wun T
    A Review of Sickle Cell Disease-Reply.
    JAMA. 2022;328:1979-1980.
    >> Share

  11. LARKIN HD
    Gene Therapy for Sickle Cell Disease, beta-Thalassemia Enters Regulatory Reviews.
    JAMA. 2022;328:1798.
    >> Share

    October 2022
  12. KUEHN BM
    Children With Sickle Cell Anemia Not Receiving Recommended Care.
    JAMA. 2022;328:1583-1584.
    >> Share

    September 2022
  13. RUBIN R
    New Gene Therapy for beta-Thalassemia.
    JAMA. 2022;328:1030.
    >> Share

    August 2022
  14. SLOMSKI A
    Sickle Cell Trait Associated With Kidney Failure and COVID-19 Death.
    JAMA. 2022;328:415.
    >> Share

    July 2022
  15. KAVANAGH PL, Fasipe TA, Wun T
    Sickle Cell Disease: A Review.
    JAMA. 2022;328:57-68.
    >> Share

    June 2022
  16. OSHIMA T, Kinjo K, Kinjo M
    Chronic Abdominal Pain and Anemia in a 59-Year-Old Man.
    JAMA. 2022 Jun 24. pii: 2793812. doi: 10.1001/jama.2022.9194.
    >> Share

    February 2022
  17. SLOMSKI A
    Oral Daprodustat Treats Anemia in Chronic Kidney Disease.
    JAMA. 2022;327:710.
    >> Share

    October 2021
  18. ABOU BAKER NM, Davis AM
    Gastrointestinal Evaluation of Iron Deficiency Anemia.
    JAMA. 2021;326:1624-1625.
    >> Share

    September 2021
  19. KENTER MJH, Cohen AF
    Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease.
    JAMA. 2021;326:974-975.
    >> Share

  20. GURKAN UA
    Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease.
    JAMA. 2021;326:975.
    >> Share

  21. CASELLA JF, Kronsberg SS, Gorney RT
    Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease-Reply.
    JAMA. 2021;326:975-976.
    >> Share

    July 2021
  22. ZHANG H, Kilaru AS, Meisel ZF, Bao Y, et al
    Prescription Drug Monitoring Program Mandates and Opioids Dispensed Following Emergency Department Encounters for Patients With Sickle Cell Disease or Cancer With Bone Metastasis.
    JAMA. 2021;326:274-276.
    >> Share

    June 2021
  23. SATO T, Terada R, Ikeda T
    Effect of Restrictive or Liberal Blood Transfusion on Major Cardiovascular Events in Patients With Acute Myocardial Infarction and Anemia.
    JAMA. 2021;325:2505-2506.
    >> Share

  24. DUCROCQ G, Simon T, Steg PG
    Effect of Restrictive or Liberal Blood Transfusion on Major Cardiovascular Events in Patients With Acute Myocardial Infarction and Anemia-Reply.
    JAMA. 2021;325:2506-2507.
    >> Share

    May 2021

  25. Foreign Letters: London.
    JAMA. 2021;325:1907.
    >> Share

    April 2021
  26. ZYLKE J
    Poloxamer 188 for Sickle Cell Disease.
    JAMA. 2021;325:1524.
    >> Share

  27. CASELLA JF, Barton BA, Kanter J, Black LV, et al
    Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
    JAMA. 2021;325:1513-1523.
    >> Share

  28. EHRENREICH H, Neubauer AP, Miskowiak K
    Effect of Early Recombinant Human Erythropoietin on Neurodevelopmental Outcomes at Age 5 Years.
    JAMA. 2021;325:1470-1471.
    >> Share

  29. NATALUCCI G, Bucher HU, Fauchere JC
    Effect of Early Recombinant Human Erythropoietin on Neurodevelopmental Outcomes at Age 5 Years-Reply.
    JAMA. 2021;325:1471-1472.
    >> Share

    February 2021
  30. DUCROCQ G, Gonzalez-Juanatey JR, Puymirat E, Lemesle G, et al
    Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial.
    JAMA. 2021;325:552-560.
    >> Share

    January 2021
  31. ABBASI J
    Promising Strategies for Sickle Cell Disease and beta-Thalassemia.
    JAMA. 2021;325:121.
    >> Share

    December 2020
  32. NATALUCCI G, Latal B, Koller B, Ruegger C, et al
    Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants.
    JAMA. 2020;324:2324-2327.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016